FDA Approves KardiaBand for Apple Watch

KardiaBand is available for $199 and requires subscription to AliveCor's Premium service for $99 a year
KardiaBand is available for $199 and requires subscription to AliveCor's Premium service for $99 a year

AliveCor announced that the Food and Drug Administration (FDA) has cleared the KardiaBand device, a new medical device accessory that allows individuals with the Apple Watch to record their EKG at any moment to detect normal sinus heart rhythms and atrial fibrillation. 

The KardiaBand can capture an EKG in 30 seconds, displaying the results on the face of the Apple Watch. The KardiaBand features SmartRhythm technology that continuously analyzes heart activity and physical activity via artificial intelligence and data from the Apple Watch's heart rate and activity sensors. If the user's heart rate and activity appear out of sync, the device alerts the user to capture an EKG with KardiaBand or KardiaMobile—the portable EKG reader. 

The KardiaBand allows for unlimited EKG recordings which can be emailed to anyone. Moreover, the combined system offers unlimited cloud history and reporting of all EKGs ever taken, weight and management tracking, and a mailed monthly paper report of EKGs taken each month. 

Related Articles

"These capabilities will allow people to easily and discreetly check their heart rhythms when they may be abnormal, capturing essential information to help doctors identify the issue and inform a clear path of care to help manage AFib, a leading cause of stroke, and other serious conditions," stated Vic Gundotra, CEO, AliveCor.

KardiaBand requires a subscription to AliveCor's Premium service. 

For more information call (855) 338-8800 or visit AliveCor.com.